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Abstract
Arachidonic acid and docosahexaenoic acid (DHA) released by the action of phospholipases  A2  (PLA2) on membrane phos-
pholipids may be metabolized by lipoxygenases to the anti-inflammatory mediators lipoxin A4 (LXA4) and resolvin D1 
(RvD1), and these can bind to a common receptor, formyl-peptide receptor 2 (FPR2). The contribution of this receptor to 
axonal or dendritic outgrowth is unknown. The present study was carried out to elucidate the distribution of FPR2 in the rat 
CNS and its role in outgrowth of neuronal processes. FPR2 mRNA expression was greatest in the brainstem, followed by the 
spinal cord, thalamus/hypothalamus, cerebral neocortex, hippocampus, cerebellum and striatum. The brainstem and spinal 
cord also contained high levels of FPR2 protein. The cerebral neocortex was moderately immunolabelled for FPR2, with 
staining mostly present as puncta in the neuropil. Dentate granule neurons and their axons (mossy fibres) in the hippocampus 
were very densely labelled. The cerebellar cortex was lightly stained, but the deep cerebellar nuclei, inferior olivary nucleus, 
vestibular nuclei, spinal trigeminal nucleus and dorsal horn of the spinal cord were densely labelled. Electron microscopy 
of the prefrontal cortex showed FPR2 immunolabel mostly in immature axon terminals or ‘pre-terminals’, that did not form 
synapses with dendrites. Treatment of primary hippocampal neurons with the FPR2 inhibitors, PBP10 or WRW4, resulted 
in reduced lengths of axons and dendrites. The CNS distribution of FPR2 suggests important functions in learning and 
memory, balance and nociception. This might be due to an effect of FPR2 in mediating arachidonic acid/LXA4 or DHA/
RvD1-induced axonal or dendritic outgrowth.
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Cognition · Brain development · Synaptic plasticity · Learning and memory · Neurite · Neurites
Introduction
There has been much recent interest in the role of lipid medi-
ators in neuronal signalling. Fatty acids such as arachidonic 
acid (AA) or docosahexaenoic acid (DHA) are released 
from membrane phospholipids by cytosolic phospholipase 
 A2  (cPLA2) and calcium-independent phospholipase A2 
 (iPLA2) [1], and are subsequently metabolized by 15-lipoxy-
genase (15-LOX-1) and 5-lipoxygenase (5-LOX) to produce 
lipoxin A4 (LXA4) [2] and resolvin D1 (RvD1) [3] or neu-
roprotectin D1 [4]. Unlike most other metabolites of arachi-
donic acid, LXA4 is an anti-inflammatory and pro-resolving 
lipid mediator that facilitates the resolution of inflammation 
[5, 6]. It promotes the recruitment of macrophages to clear 
cellular debris [7, 8], and inhibits macrophage / microglial 
activation and reduces neuropathic pain [9]. RvD1 is a 
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potent pro-resolvin lipid mediator that limits polymorpho-
nuclear leukocyte recruitment to inflammatory loci [10], and 
neuroprotectin D1 reduces expression of pro-inflammatory 
factors and protects human retinal pigment epithelial cells 
from oxidative stress [11]. Both LXA4 and RvD1 activate a 
G-protein coupled receptor (GPCR), formyl-peptide recep-
tor 2 (FPR2) (also known as FPR-L1) [12]. The latter is a 
member of the FPR family of seven transmembrane GPCRs 
originally identified as anti-microbial receptors on the sur-
face of neutrophils and monocytes/macrophages [13].
FPRs mediate cell chemotaxis in a pertussis toxin-sensi-
tive manner, indicating coupling to the Gi (inhibitory) sub-
family of G proteins [13]. The N-formyl group is a crucial 
determinant of ligand binding to FPR [14]. Since bacterial 
[15, 16] and mitochondrial proteins [17] are the only sources 
of N-formyl peptides in nature, it widely thought that these 
receptors mediate trafficking of phagocytes to sites of bacte-
rial invasion or tissue damage [13]. The FPRs are involved in 
host defence against bacterial infection, and in the clearance 
of damaged cells [13]. For example, human FPR2 detects 
bacterial endotoxins including peptides released by Staphy-
lococcus aureus, and specific blocking of FPR2 severely 
diminished neutrophil detection of endotoxin and leuko-
cyte infiltration [18]. Activation of FPR2 leads to transient 
calcium ion mobilization [19], ERK phosphorylation [19] 
and cell motility [20]. Nevertheless, since FPR2 is activated 
only with high concentrations of N-formyl oligopeptides in 
the micromolar range in vitro, it is considered a low-affinity 
receptor for bacterial peptides [21].
FPRs also bind a large and diverse group of lipid and 
protein ligands with high affinity. For example, FPR2 binds 
potently to LXA4 in the nanomolar range and is also known 
as the lipoxin receptor or LXR [12]. Many studies have dem-
onstrated the interaction between FPR2 and LXA4 or RvD1 
that mediates the anti-inflammatory, pro-resolving and anti-
nociceptive actions of these lipid mediators [10, 22–26]. 
FPR2 binds to annexin I (lipocortin I) [27], an endogenous 
glucocorticoid-regulated protein that has anti-inflammatory 
activities [28, 29]. The presence of three FPR family mem-
bers, Fpr1, Fpr-rs1 and Fpr-rs2, has been reported in the 
hippocampus and hypothalamus of the mouse [30, 31]. A 
survey of the distribution of FPR2 / FPR-L1 has been car-
ried out at the light microscopic level in human organs, tis-
sues and cells, including the brain, and dense staining was 
reported, but not illustrated, in the cerebellum and brainstem 
[32]. Treatment of primary murine microglial cells with 
lipopolysaccharide results in activation of these cells, and 
this effect is mediated by FPR [13].
There is much recent interest in the role of lipid media-
tors as signalling molecules in the brain. In particular, recent 
findings suggest that lipid anti-inflammatory molecules 
could have a role in processes such as long term potentiation 
and memory formation [33–37]. However, the contribution 
of FPR2 to axonal or dendritic outgrowth is unknown. The 
present study was carried out, to elucidate the expression 
and localization of FPR2 at the mRNA, protein, immuno-
histochemical and ultrastructural level in the rat CNS, and 




Adult male Wistar rats (250–300 g) were purchased from 
the Centre for Animal Resources (CARE), National Uni-
versity of Singapore, and housed in temperature con-
trolled (23 ± 1 °C), individually ventilated cages on a 12-h 
light–dark cycle (7AM-7PM) with access to food and water. 
Rats were acclimatized for 4 days before the start of experi-
ments. All procedures were in accordance with the Princi-
ples of Laboratory Animal Care, and approved by the Insti-
tutional Animal Care and Use Committee of the National 
University of Singapore.
Real‑Time Reverse Transcriptase Polymerase Chain 
Reaction (RT‑PCR)
Four adult male Wistar rats were used for this portion of the 
study. Rats were deeply anesthetized with a ketamine/xyla-
zine cocktail and sacrificed by decapitation. Ketamine/xyla-
zine mixture used was prepared in saline (ketamine (75 mg/
kg), xylazine (10 mg/kg), in 0.9% sodium chloride solution). 
Various parts of the rat brain including olfactory bulb, pre-
frontal cortex, striatum, thalamus/hypothalamus, hippocam-
pus, cerebral cortex (labelled CTX1 and CTX2), cerebellum 
and brainstem were dissected out. The spinal cord was har-
vested and sub-divided into the cervical [SC(C)], thoracic 
[SC(T)] and lumbar [SC(L)] segments. CTX1 contained the 
motor and somatosensory cortices, whereas CTX2 included 
the parietal association and auditory cortices. Tissues were 
snap frozen in liquid nitrogen and stored at − 80 °C. Total 
RNA was extracted using TRizol reagent (Invitrogen, CA, 
USA) according to manufacturer’s protocol. RNeasy® Mini 
Kit (Qiagen Inc., Hilden, Germany) was used to purify the 
RNA. Samples were treated with RNase-Free DNase (Qia-
gen Inc., Hilden, Germany) to remove any contaminating 
DNA, and reverse transcribed using High Capacity cDNA 
Reverse Transcription Kits (Applied Biosystems, CA, 
USA). Reaction conditions were 25 °C for 10 min, 37 °C for 
120 min and 85 °C for 5 s. Real-time PCR amplification was 
performed using 7500 Real time PCR system (Applied Bio-
systems) on TaqMan® Universal PCR Master Mix (Applied 
Biosystems), FPR2 (Rn03037051_gH) and β-actin probes 
(#4352340E) (Applied Biosystems, CA, USA) according to 
1589Neurochemical Research (2018) 43:1587–1598 
1 3
the manufacturer’s instructions. The PCR conditions were: 
incubation at 50 °C for 2 min and 95 °C for 10 min fol-
lowed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. 
All reactions were carried out in triplicates. The threshold 
cycle (CT) was measured as the number of cycles which the 
reporter fluorescence emission exceeds the pre-set threshold 
level. Using the 2−ΔΔCT method, the relative fold changes 
were quantified by first obtaining the threshold cycle, CT 
that inversely correlates with the levels of mRNA present in 
the sample. All reactions were performed in triplicates, and 
the mean and standard error calculated.
Western Blot Analysis
Proteins were first extracted from different regions of the 
brain and spinal cord using T-PER® Tissue Protein Extrac-
tion solution containing 1% HaltTM protease inhibitor and 
1% EDTA solution (Thermo Fisher Scientific, IL, USA). 
Concentrations of the protein obtained were measured using 
the Bio-Rad protein assay kit. Protein samples (30 µg) were 
mixed with a loading dye consisting of SDS and DTT, dena-
tured at 95–100 °C for 10 min and resolved in 10% SDS–pol-
yacrylamide (SDS–PAGE) gels under reducing conditions. 
A protein ladder was used to monitor the electrophoresis 
run and to check for protein size as well as protein trans-
fer efficacy (Precision Plus Protein Dual Colour Standards, 
Bio-Rad Laboratories, CA, USA). Resolved proteins were 
electrotransferred to a polyvinylidene difluoride (PVDF) 
membrane and non-specific binding sites were blocked by 
incubation for 1 h with 5% non-fat milk in Tris-buffered 
saline containing 0.1% Tween-20 (TBST). After blocking, 
the PVDF membrane was incubated overnight with FPR2 
antibody (NLS1878, Novus Biologicals, CO, USA; diluted 
1:1000 in 5% non-fat milk in TBST) at 4 °C. Peptide compe-
tition assay was carried out with 5 × protein concentration of 
the peptide antigen (NLS1878PEP, Novus Biologicals, CO, 
USA). The PVDF membrane was then washed with TBST 
and incubated with horseradish peroxidase-conjugated 
anti-rabbit IgG (Thermo Fisher Scientific, IL, USA; diluted 
1:2000 in 5% non-fat milk in TBST) for 1 h at room tem-
perature. Protein bands were visualized with an enhanced 
chemiluminescence kit (Supersignal West Pico, Thermo 
Fisher Scientific, IL, USA). For loading controls, the mem-
brane was incubated with a stripping buffer for 10 min at 
room temperature (Restore Western Blot Stripping Buffer, 
Thermo Fisher Scientific, IL, USA). The membrane was 
again blocked with 5% non-fat milk in TBST before incu-
bating with a mouse monoclonal antibody to beta-actin (Sig-
maAldrich, MO, USA; diluted 1:10,000 in 5% non-fat milk 
in TBST) for 30 min at room temperature. The membrane 
was then incubated with horseradish peroxidase-conjugated 
anti-mouse IgG (Thermo Fisher Scientific, IL, USA; diluted 
1:10,000 in 5% non-fat milk in TBST) for 30 min. The 
densities of the 38 kDa band corresponding to the predicted 
molecular weight of FPR2 without posttranslational modifi-
cations, were obtained from the different brain regions, and 
normalized to that of β-actin, using the Gel-Pro Analyzer3.1 
program (Media Cybernetics, MD, USA).
Immunohistochemistry
Four adult Wistar rats were used for this portion of the study. 
They were deeply anesthetized and perfused through the left 
cardiac ventricle with a solution of 4% paraformaldehyde 
and 0.1% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). 
The brains were removed and sectioned coronally at 100 µm 
using a vibrating microtome (Leica, Wetzlar, Germany). The 
free-floating sections were washed with repeated changes 
of phosphate-buffered saline (PBS) for 3 h, and incubated 
overnight with an affinity-purified rabbit polyclonal antibody 
to FPR2 (NLS1878, Novus Biologicals, CO, USA), diluted 
1:500 in PBS. Peptide competition assay was carried out 
using antigen-absorbed antibody as described above. Sec-
tions were incubated for 1 h in a 1:200 dilution of bioti-
nylated anti-rabbit IgG (Vector, Burlingame, CA), followed 
by 1 h incubation with avidin–biotin complex. They were 
stained for FPR2 using a mixture of 3,3′-diaminobenzidine 
tetrahydrochloride (Sigma-Aldrich, MO, USA) in nickel-Tris 
buffered saline containing 0.05% hydrogen peroxide. Some 
of the sections were mounted on glass slides and counter-
stained with methyl green followed by coverslipping. The 
remaining sections were processed for electron microscopy.
Transmission Electron Microscopy
Electron microscopy was carried out by subdissecting some 
of the immunostained sections of the prefrontal cortex into 
smaller portions. These were post-fixed with 1% osmium 
tetroxide, dehydrated in an ascending series of ethanol and 
acetone, and embedded in Araldite. Thin sections were 
obtained from the first 5 µm of the sections, mounted on 
copper grids coated with Formvar, and stained with lead 
citrate. They were viewed using a JEOL 1010 EX electron 
microscope (JEOL, Tokyo, Japan).
Preparation of Rat Hippocampal Neurons
Hippocampal neurons were prepared as previously 
described with modifications [38]. Postnatal (P)0 or P1 MPF 
HanTac:WH (Wistar) rat pups were decapitated and hip-
pocampi were rapidly isolated from their brains in a neutral 
(pH 7.3) dissection solution (mGBSS) containing common 
salts, glucose and HEPES (Sigma) at 4 °C in 35 mm diam-
eter dishes. Meninges and dentate gyrus were removed prior 
to the separation of the hippocampus. Following this, dis-
sected hippocampi were enzymatically digested by 0.25% 
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trypsin (Life Technologies, Carlsbad, USA) in a humidified 
incubator (37 °C, 5%  CO2) for 30 min. Trypsin was removed 
and hippocampi slices were triturated up and down for ten 
times with a siliconized 9 in Pasteur pipette consisting of a 
fire polished tip opening of approximately 0.7–0.9 mm in 
diameter. After the hippocampi have settled to the bottom (in 
about 2 min), the supernatant was collected and the remain-
ing sediments were triturated twice more for 10 and 8 times 
respectively in 5% serum medium containing MEM Eagle 
modified (Sigma), glucose, 2 mM glutamine, MEM-vitamin, 
Mito + Serum extender (Corning, New York, USA) and fetal 
bovine serum (FBS). The resulting cell suspension was cen-
trifuged at 500 g for 5 min and the cell pellet resuspended 
in neuronal plating media comprising DMEM/F12 Ham’s 
Nutrient Mixture (Sigma), 0.5 mM glutamine and B27 (Life 
Technologies). Cells were plated on HCl-treated glass cov-
erslips coated with poly-D-lysine at a density of 30,000 cells 
per 12-well plate or 4,000 cells per 96-well plate.
Cell Viability Assays
Cytotoxicity profiling was performed in 96-well transpar-
ent plates with Alamarblue® (Invitrogen®) cell viability 
reagent. PBP10 and WRW4 were purchased from Tocris 
Bioscience and diluted in water to obtain 5 and 8 mM stock 
solutions, respectively. Further dilutions to working con-
centrations of each compound were achieved by diluting in 
neuronal plating media. To determine the optimal dosage for 
each drug, neurons plated in 96-well plates were exposed to 
a range of concentrations of PBP10 or WRW4 (1.25–10 µM) 
for 24 h. Non-drug treated samples were treated with vehicle 
control (water). PBS was used to wash each well twice prior 
to the addition of 100 µl of Alamarblue® mixture consisting 
of 10 µl Alamarblue® reagent and 90 µl of neuronal plating 
media. After 4 h of incubation in the dark, fluorescence from 
individual wells was measured using the TECANTM Reader 
(Infinite® 200 PRO series) employing excitation and emis-
sion wavelengths of 570 and 585 nm, respectively.
Axon and Dendrite Growth Assays
Hippocampal neurons grown 1 day in vitro (DIV) were 
treated with 5 µM of PBP10 or 7.5 µM of WRW4 for 3 days. 
Control samples were treated with vehicle control (water). 
Cells were fixed with 3.7% paraformaldehyde (Sigma) at 
the end of 3 days and permeabilised with 0.3% Triton-X 
(Sigma). The fixed samples were then rinsed with PBS and 
blocked with 10% normal goat serum (Merck) at room tem-
perature for 30 to 45 min. Cells were incubated with primary 
antibodies against MAP2 (polyclonal rabbit anti-MAP2, 
Synaptic Systems, dilution 1:400) and Tau (polyclonal 
guinea pig anti-Tau, Synaptic Systems, dilution 1:400) at 
room temperature for 1 h before three consecutive washes 
with PBS to remove excess antibodies. Following this, cells 
were incubated with secondary antibodies (Cy2-conjugated 
donkey anti-rabbit, dilution 1:200; Cy3-conjugated donkey 
anti-guinea pig, dilution 1:400; both from Jackson Immu-
noResearch) for 1 h at room temperature. Cells were further 
washed with PBS prior to mounting onto glass slides with 
Fluoro-Gel II with DAPI (Electron Microscopy Sciences).
Quantification of Axon and Dendrite Lengths
Images of individual neurons per treatment (that is, with 
or without drugs) were acquired and tiled using a Zeiss 
Axio Observer Z1 Microscope equipped with a motorised 
stage. Total axon and dendrite lengths were measured using 
the semiautomatic tracing function in the NeuronJ plugin 
of ImageJ. Possible differences in neurite lengths between 
drug-treated (PBP10 or WRW4) and vehicle treated con-
trols, were analysed using one-way ANOVA with Dunnett’s 
post-test using GraphPad Prism 6.0 software. p < 0.05 was 
considered significant.
Results
Expression of FPR2 mRNA in the Rat CNS
The relative expression levels of FPR2 mRNA in the brain 
and spinal cord were determined by real-time RT-PCR 
(Fig. 1). Results showed that the striatum had the lowest 
level of FPR2 mRNA expression. Hence all fold changes 
were normalized to that of the striatum. The brainstem (BS) 
had the greatest FPR2 mRNA expression level, followed by 
the spinal cord lumbar [SC(L)], spinal cord cervical [SC(C)], 
thalamus/hypothalamus (THA), spinal cord thoracic [SC(T)] 
and prefrontal cortex (PFC). Low levels of FPR2 mRNA 
were found in the olfactory bulb, hippocampus, cerebellum 
and striatum (Fig. 1).
Expression of FPR2 Protein in the Rat CNS
Western blot analysis showed that the FPR2 antibody rec-
ognised two major bands and one diffuse band. Blots incu-
bated with antigen-absorbed antibody showed reduced 
density of the bands, indicating specificity of the antibody 
(Fig. 2a). The major band of approximately 38 kDa and the 
diffuse band of 39 kDa represent the non-glycosylated form 
of FPR2. The other major 55 kDa band is likely a glyco-
sylated form of FPR2. Quantitative densitometric analysis 
of the 38 kDa band corresponding to the molecular weight 
of FPR2 without posttranslational modifications, revealed 
the brainstem had the highest expression, followed by the 
cervical spinal cord, thalamus/hypothalamus, lumbar spinal 
cord, cerebellum, primary and secondary motor cortex and 
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the primary somatosensory cortex (CTX1), parietal associa-
tion cortex and secondary auditory cortex (CTX2), thoracic 

























Expression of FPR2 mRNA in the CNS
Fig. 1  Real-time RT-PCR analysis of FPR2 mRNA expression in var-
ious parts of the rat brain including olfactory bulb (OB), prefrontal 
cortex (PFC), primary somatosensory cortex (CTX1), parietal associ-
ation cortex and secondary auditory cortex (CTX2), striatum (STR), 
thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum 
(CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal 
cord [SC(T)], and lumbar spinal cord [SC(L)].Fold change values 
were normalized to the lowest expressing FPR2 mRNA in the stria-
tum. Data represents mean and standard error from 4 Wistar rats
Fig. 2  a Immunoblot of FPR2 
protein in various parts of the 
rat brain including olfactory 
bulb (OB), prefrontal cortex 
(PFC), primary somatosensory 
cortex (CTX1), parietal associa-
tion cortex and secondary audi-
tory cortex (CTX2), striatum 
(STR), thalamus and hypo-
thalamus (THA), hippocam-
pus (HPC), cerebellum (CB), 
brainstem (BS), cervical spinal 
cord [SC(C)], thoracic spinal 
cord [SC(T)], and lumbar spinal 
cord [SC(L)]. Blots incubated 
with antigen-absorbed antibody 
i.e. peptide competition, show 
reduced band intensities. b 
Densities of the 38 kDa band 
corresponding to the molecular 
weight of FPR2 without post-
translational modifications nor-
malized to that of β-actin. Data 
represents mean and standard 
error from four Wistar rats
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Immunohistochemistry
Sections incubated with antibody neutralised by the block-
ing peptide showed absence of immunostaining, indicating 
specificity of immunoreaction (Fig. 3a). Moderately dense 
staining was observed in the olfactory bulb (Fig. 3b). The 
cerebral cortex was moderately labelled (Fig. 3c). Little or 
no staining was observed in neuronal cell bodies. Instead, 
staining was observed as punctuate profiles in the neuropil. 
These were found to be mostly axon pre-terminals at elec-
tron microscopy (see below). The hippocampal formation 
was lightly stained, except for the cell bodies, dendrites, 
and axons of dentate granule neurons (mossy fibres) which 
were very densely labelled. The mossy fibres appeared as a 
characteristic band in the stratum lucidum of CA3 (Fig. 3d). 
The amygdala (Fig. 3e) and striatum (Fig. 3f), including the 
caudate putamen (Fig. 3f) were lightly labelled. As with the 
cerebral neocortex, label was mostly absent from cell bodies, 
but present as punctuate profiles in the neuropil. The globus 
pallidus was very lightly labelled or unlabelled (Fig. 3f). 
The thalamus was lightly labelled (Fig. 3g), while the hypo-
thalamus was moderately labelled (Fig. 3h). The cerebellar 
cortex contained scattered labelled Purkinje neurons, but 
was otherwise unlabelled (Fig. 4a). Dense staining was, 
however, observed in the deep cerebellar nuclei (Fig. 4b), 
and nuclei in the brainstem that are connected to the cer-
























Fig. 3  Sections from the forebrain. a Sections labelled with antigen-
absorbed antibody, showed absence of labelling. b Moderately dense 
staining is present in the olfactory bulb. c The cerebral cortex (CX) 
is moderately labelled. Staining is present in punctuate profiles in the 
neuropil. d The cell bodies, dendrites (DG) and axons (mossy fibres, 
MF) of dentate granule neurons are densely labelled. e The amyg-
dala (AM) is lightly labelled. f The caudate-putamen (CP) is lightly 
labelled. The globus pallidus (GP) is very lightly labelled or unla-
belled. g The thalamus is lightly labelled. h The hypothalamus (HT) 












Fig. 4  Sections in the hindbrain and spinal cord. a The cerebel-
lar cortex contained scattered, lightly labelled Purkinje neurons. b 
Dense staining is present in the deep cerebellar nuclei, including the 
dentate nucleus (DN). c The inferior olivary nucleus (IO) is densely 
labelled. d The vestibular nuclei (VN) are densely labelled. e The 
dorsal and ventral cochlear nuclei (CN), and the spinal trigeminal 
nucleus (V) are densely labelled. f The facial motor nucleus (VII) is 
densely labelled. g The dorsal horn of the spinal cord (DH) is densely 
labelled. h The ventral horn (VH) of the spinal cord is moderately 
densely labelled. Scale: a–f: 0.5 mm. g, h = 250 µm
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vestibular nuclei (Fig. 4d). The dorsal and ventral cochlear 
nuclei (Fig. 4e), the spinal trigeminal nucleus (Fig. 4e) and 
the facial motor nucleus (Fig. 4f) were densely labelled. 
Dense labelling was observed in the superficial portion of 
the dorsal horn (Fig. 4g), while moderate staining was found 
in the ventral horn (Fig. 4h) of the spinal cord.
Transmission Electron Microscopy
Electron microscopy of immunostained sections of the pre-
frontal cortex showed FPR2 label was mostly present in 
axon pre-terminals with small round synaptic vesicles that 
did not form synapses with dendrites (Fig. 5a, b). Occa-
sional labelled axon terminals were observed to form asym-
metrical, putatively glutamatergic synapses with unlabelled 
dendrites (Fig. 5c), and occasional, labelled dendrites were 
found that formed asymmetrical synapses with unlabelled 
axon terminals (Fig. 5d). Glial cells and blood vessels were 
unlabelled.
Inhibition of FPR2 Signalling Reduces Axon 
and Dendrite Growth
To examine the possible roles of FPR2 in neurons, we 
exposed developing hippocampal neurons to the FPR2 inhib-
itors WRW4 or PBP10. WRW4 is a six amino acid peptide 
that has been shown to block FPR2 signalling by inhibiting 
the binding of FPR2 agonists [39]. PBP10 is a ten-amino 
acid long, membrane permeable peptide derived from gel-
solin that inhibits FPR2 signalling by blockade of several 
FPR2-mediated downstream processes [40, 41]. We postu-
lated that inhibition of FPR2 signalling could affect axonal 
outgrowth in developing neurons. To determine this, we 
exposed primary hippocampal neurons to increasing doses 
of WRW4 or PBP10 to determine the optimal concentration 
to be used for each drug. We decided to expose the neurons 
to 5 µM (PBP10) and 7.5 µM (WRW4) since more than 
80% of the treated neurons remained viable when analysed 
by the Alamarblue cell viability assay, when the drugs were 
used at or below these concentrations (Fig. 6a, b). Strik-
ingly, we observed that total axonal length was significantly 
decreased in drug-treated neurons (Fig. 6c, d). Interestingly, 
PBP10 appeared to exert a much greater effect than WRW4 
(54.8 ± 4.7% vs. 17.2 ± 3.6% reduction, respectively). This 
result is consistent with previous findings that PBP10 nega-
tively impacts actin assembly [40, 42]. Remarkably, neu-
rons exposed to both drugs also demonstrated significant 
reductions in total dendritic length (Fig. 6e). Importantly, 
the Alamarblue cell viability assay detects the metabolic 
activity of a cell based on the oxidation–reduction (REDOX) 
potentials of molecules involved in the electron transport 
chain, which takes place in the mitochondria [43]. Given that 
both mitochondrial function and homeostasis are intact with 
the dosage used, local demands of ATP supply and calcium 
buffering capacity are therefore normal. This indicates that 
the viable cells are still able to grow normally with no effects 
Fig. 5  Electron micrographs of 
FPR2 immunostained sections 
from the prefrontal cortex. a, 
b Immunostaining is mostly 
present in axon pre-terminals 
(PrT) that did not form synapses 
with postsynaptic structures. c 
Occasional axon terminals (AT) 
are observed to form asym-
metrical, putatively glutamater-
gic synapses (S) with unlabelled 
dendrites (DE). d Occasional 
labelled dendrites (DE) are also 
found, that formed asymmetri-
cal synapses (S) with unlabelled 
axon terminals (AT). Scale: a, 
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Fig. 6  Treatment with WRW4 and PBP10 negatively affects axon 
and dendrite outgrowth in developing hippocampal neurons. Hip-
pocampal neurons were exposed to increasing doses of PBP10 (a) or 
WRW4 (b) a day after plating and cell viability was evaluated 1 day 
after treatment. Drug concentrations below 5 and 7.5  µM showed 
more than 80% cell viability (indicated by the blue dotted lines) for 
PBP10 and WRW4 respectively. c Representative immunofluores-
cence microscopy images showing Tau (an axonal marker, in red) 
and MAP2 (a dendritic marker, in green) in drug-treated (PBP10 or 
WRW4) or vehicle-treated neurons with their respective axon and 
dendrite traces. Quantitative analyses of mean total dendrite length 
(d) and mean total axon length (e) in drug- or vehicle-treated neu-
rons. While both WRW4 and PBP10 reduced axonal and total den-
dritic lengths in comparison to the vehicle-treated control, PBP10 
demonstrated a stronger effect in reducing the axon length while 
WRW4 exhibited a larger influence in decreasing total dendritic 
length. Data was derived from two independent experiments. Error 
bars represent SEM. Scale bar in c correspond to 50 µm. Statistical 
analyses in panels d and e were performed with one-way ANOVA 
and corrected using Dunnett’s post-test. ***p < 0.001; **p < 0.01; and 
*p < 0.05
1595Neurochemical Research (2018) 43:1587–1598 
1 3
from cell impairments contributing to the reductions in total 
axonal and dendritic lengths. Thus the reductions in total 
axonal and dendritic length are directly due to the effects 
of inhibiting FPR2 signalling when exposed to WRW4 or 
PBP10. Results are consistent with recent studies which 
show that FPR2 is expressed in hippocampal neural stem 
cells, and promotes differentiation into neurons with more 
and longer primary neurites per cell [44, 45].
Discussion
The present study was carried out to elucidate the expression 
and distribution of FPR2 in different regions of the brain and 
spinal cord. Real-time RT-PCR results indicate that FPR2 
mRNA is generally present in all brain regions, with higher 
expression in the brainstem and spinal cord than the fore-
brain. In particular, expression in the brainstem is double 
that of the cerebral cortex, and 16 times that of the striatum. 
The results of Western blots are generally consistent with 
that of RT-PCR, and high protein expression was found in 
the brainstem and spinal cord. Several bands were found in 
Western blots which were all absent/markedly attenuated 
in blots incubated with antigen-absorbed antibody, indicat-
ing specificity of the antibody: two bands of 38 and 39 kDa 
represent the non-glycosylated form of FPR2. The 38 kDa 
band is consistent with the expected molecular weight of 
FPR2, and the diffuse 39 kDa band is also likely a non-
glycosylated form of FPR2, while the 55 kDa band is likely 
a glycosylated form of the receptor. FPR2 is known to be 
glycosylated [46] and conserved N-glycosylation sites are 
found on the human FPR2 protein at the N-terminus (Asn4) 
and second extracellular loop (Asn179) [47]. It is likely the 
rat ortholog possesses these sites as well. A wide range of 
molecular weights of FPR2 on SDS–PAGE gels has been 
reported in the literature, ranging from 38 to 100 kDa, which 
is attributed to glycosylation or dimerization [25, 48, 49]. 
More than a single band of protein is also found in Western 
blots of FPR1, which is attributed to a mixture of non-gly-
cosylated and differently-glycosylated forms of the receptor 
[50, 51]. Glycosylation is necessary for the proper folding 
of FPR1 [51], and this is likely also for FPR2.
Immunohistochemical analyses showed absence of 
staining in sections that had been incubated with antigen-
absorbed antibody, indicating specificity of immunola-
belling. Consistent with the RT-PCR results, generally 
denser staining was observed in the brainstem and spinal 
cord than the forebrain. The cerebral cortex was mod-
erately densely immunolabelled for FPR2, and staining 
was observed as punctuate profiles in the neuropil. The 
hippocampus was lightly stained, except for dentate gran-
ule neurons and their axons (mossy fibres), which were 
densely labelled. These findings are congruent with studies 
that show that FPR2 is expressed in hippocampal neural 
stem cells [44, 45]. Since the dentate gyrus -> CA3 projec-
tion is part of a trisynaptic circuit through the hippocam-
pus for consolidation of long term memory [52], this sug-
gests an important role of FPR2 in memory formation. 
The thalamus was lightly labelled, while the hypothala-
mus was moderately densely labelled. The latter might 
account for the high levels of FPR2 mRNA and protein 
detected in this region by RT-PCR and Western blots. The 
deep cerebellar nuclei, the inferior olivary nucleus and the 
vestibular nuclei in the brainstem were densely labelled 
for FPR2. This suggests that FPR2 could be important in 
balance and motor coordination. The high level of FPR2 
immunoreactivity in the deep cerebellar nuclei, and FPR2 
protein in western blots of the cerebellum, could be due 
to a high level of translation, in view of the low level of 
mRNA expression in the cerebellum. FRP2 immunolabel 
was also observed in the spinal trigeminal nucleus and 
the dorsal horn of the spinal cord, which are sites of ter-
mination of primary nociceptive afferents. This suggests 
a role of FPR2 in the ascending pain pathway. LXA4 has 
been shown to improve learning and memory after suba-
rachnoid haemorrhage, and these effects were mediated by 
FPR2 [22]. In addition, protective effects of RvD1 against 
surgery-induced memory loss have been reported [53]. 
The findings in this study on the rat CNS are consistent 
with results of a broad survey of FPR2/FPR-L1 immunolo-
calization at the light microscopic level in human organs. 
In that study, dense staining was reported (but not illus-
trated) in the cerebellar system, including the inferior oli-
vary nucleus, vestibular nuclei, spinal trigeminal nucleus 
and dorsal horn of the spinal cord [32], reviewed in [54]. 
Previous studies have shown that Aβ oligomers accelerates 
senescence in adult hippocampal neural stem/progenitor 
cells via FPR2, and effect of LXA4 in reducing Aβ toxicity 
in the mouse brain [55, 56].
In the present study, electron microscopy showed FPR2 
immunolabel in axon pre-terminals that did not form syn-
apses with dendrites, but could instead represent growth 
processes. This was tested by examining the effect of FPR2 
inhibition in primary cultured neurons. Incubation of cells 
with concentrations of FPR2 inhibitors PBP10 or WRW4, 
that did not cause loss in cell viability, showed that inhibition 
of FPR2 signalling significantly diminished the lengths of 
axons (labelled by Tau antibody) and dendrites (labelled by 
MAP2 antibody), indicating that FPR2 is involved in axonal 
and dendritic outgrowth. Changes in neuronal polarity were 
also found (data not shown). These results are consistent 
with findings that resolvin D1 stimulates neurite outgrowth 
of primary cultured dorsal root ganglion cells from normal 
mice [57]. They are also in congruence with studies which 
show that FPR2 promotes neuronal differentiation, with 
more and longer primary neurites per cell [44, 45].
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The findings of dense FPR2 immunolabelling in the 
brainstem and cerebellum are consistent with our previous 
findings that that the enzyme that catalyses the release of 
arachidonic acid from membrane phospholipids, cytosolic 
phospholipase  A2  (cPLA2) is also present at high levels in 
the hindbrain [58] and spinal cord [59]. Arachidonic acid 
can be further metabolized by lipoxygenases Alox5 and 
Alox12 to form LXA4 [60]. It is striking that both  cPLA2 
and FPR2 are present at high levels in almost the same 
nuclei in the hindbrain. For example, the deep cerebellar 
nuclei, dorsal and ventral cochlear nuclei, spinal trigemi-
nal nucleus, and dorsal horn of the spinal cord contain 
high levels of immunostaining to both  cPLA2 [58, 59] 
and FPR2 (this study). These observations suggest that 
the major ligand of FPR2 in the normal brainstem and 
cerebellum is LXA4.
In contrast to the brainstem and spinal cord, the cer-
ebral cortex and hippocampus contain much lower levels 
of  cPLA2 expression [58]. However, another  PLA2 iso-
form that is present at high levels in the cortex, which 
could also release arachidonic acid for LXA4 formation, 
is secretory phospholipase  A2 XIIA  (sPLA2 XIIA) [61]. 
Lipidomic analyses of the prefrontal cortex after antisense 
knockdown of  sPLA2 XIIA reveal changes in phospholipid 
and lysophospholipid species, which are consistent with 
a role of this enzyme in the endogenous release of ara-
chidonic acid. Antisense oligonucleotide knockdown of 
 sPLA2 XIIA in the prefrontal cortex results in deficits in 
the attention set shifting task [61].
RvD1 is also a ligand for FPR2. RvD1 interacts with 
FPR2 [23], and attenuates inflammation and promotes 
functional recovery after focal brain damage [62]. The 
enzyme calcium independent phospholipase  A2  (iPLA2) 
preferentially releases DHA from brain membrane phos-
pholipids. DHA is metabolized by Alox15 and Alox5 to 
RvD1. Both  iPLA2 [63] and Alox15 [33] are expressed at 
high levels in the forebrain, including the cerebral cortex. 
Hence, it is possible that besides LXA4, RvD1 is a ligand 
for FPR2 in the cerebral cortex.
In conclusion, the present study adds to recent findings 
that show an important role of anti-inflammatory mol-
ecules in neural signalling [33], by demonstrating that a 
receptor for lipoxin A4 and resolvin D1, FPR2, is present 
in specific locations in the brain and spinal cord. Further 
studies are necessary to elucidate the in vivo function of 
FPR2 in the CNS.
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